Solex Energy Q1 FY27: A soft start, a heavy cost base, and a clear push toward integration

Solex Energy opened FY27 with numbers that reflected a familiar reality for utility-scale solar suppliers in India. Q1 is typically the softest quarter, and this year the quarter also carried the impact of policy-driven uncertainty around ALMM and ALCM timelines. The company reported total revenue of INR 265.6 crore in Q1 FY27, up 1.8 percent year-on-year, but profitability was meaningfully lower. EBITDA came in at INR 33.8 crore with a margin of 12.7 percent, while PAT was INR 8.3 crore with a margin of 3.1 percent.

Management framed the quarter as a timing issue rather than a demand issue. In the post-results concall, the company emphasised that delivery schedules were deferred by customers who entered a wait-and-watch mode after the ALMM and ALCM clarifications in late May. Importantly, it described these as shifts, not cancellations, and stated it did not see orders at risk.

What shaped Q1: stable revenue, weaker profitability

Net sales were INR 260.8 crore in Q1 FY27 versus INR 259.6 crore in Q1 FY26, indicating that topline held steady despite a softer industry environment. The bigger story was below the EBITDA line. Depreciation rose sharply to INR 10.2 crore from INR 4.3 crore a year earlier. Finance costs increased to INR 12.5 crore from INR 5.4 crore. The CFO attributed this to the full-quarter impact of the additional module lines and higher working capital usage, including a greater reliance on fund-based limits.

This matters because Solex has expanded to a 4 GW module manufacturing base, and in a low-volume quarter, fixed costs get absorbed across a smaller revenue pool. Management was direct that this is the underlying dynamic in Q1 and Q2 and that execution typically accelerates post-monsoon.

Order visibility and the ALMM and ALCM overhang

The company stated an order book visibility of about INR 3,400 crore. It described this visibility as spread across confirmed purchase orders under execution, signed MSAs where formal POs are awaited, and MSAs in advanced discussion. Management’s core assertion was that visibility is not contingent on the ALMM-2 outcome because the company is positioned for both scenarios.

For ALCM-compliant orders, Solex said it has supply arrangements with domestic cell manufacturers. For other orders, it stated it is secured on imported cell supply. In the concall, management also indicated that only a portion of the book had vulnerability from ALCM-driven delays and said that the subsequent extension clarity reduced the immediate uncertainty.

The company also highlighted specific orders that it expects to execute in the near term. Management referenced a module order of about INR 628 crore received in July 2026, a further INR 42.47 crore order in August 2026, and an LOI for INR 175 crore with an MSA at signing stage. Together, it stated these total INR 845.84 crore and are targeted for execution before December 31, 2026.

Capacity, utilisation expectations, and why FY27 assumptions are conservative

Solex currently has 4 GW of module capacity and the management said it is working with an average utilisation assumption of around 55 percent for FY27. On the face of it, this looks conservative. In the concall, the company explained this posture as a reflection of the wider industry disruption and the increase in capacity base from 1.5 GW earlier to 4 GW now.

The broader rationale is that the module market has significant capacity additions across India, while domestic cell availability is still evolving for DCR and ALCM-linked demand. Management suggested that cell availability will improve as new lines ramp, and that the company expects its DCR cell requirement to rise meaningfully from April 2027 onwards.

This conservative utilisation stance also influences how investors interpret quarterly earnings. With a larger asset base, the quarterly swings between H1 and H2 can appear more pronounced, especially when depreciation and interest costs have stepped up.

The strategic pivot: from module maker to integrated platform

The most consequential part of the concall was the emphasis on cell manufacturing as a medium-term margin inflection rather than just an expansion headline. The company reiterated its plan for a 5 GW cell project executed in two phases. Phase 1 is a 2.2 GW N-type TOPCon plus cell line, targeted for commissioning by end of calendar year 2027.

Management said the land parcel is in the closing stage and it has applied for a 30 MW power connection in Gujarat, with verbal approval received and written approval awaited. On funding, it described the debt portion of around INR 700 crore as being in advanced discussions with a lender. The equity portion of around INR 350 crore is described as structured via instruments including NCDs and CCDs, with due diligence underway.

A key operational mitigation strategy was also stated: onboarding an experienced TOPCon cell manufacturer on a KPI-linked basis for line design, commissioning, and operations. Management positioned this as a deliberate choice given the known ramp-up challenges faced by several cell projects in India.

The long-term roadmap remains ambitious. The presentation outlines a Vision 2030 path toward 10 GW module manufacturing, 10 GW cell manufacturing, 10 GW of BESS infrastructure, and 2 GW ingot and wafer capacity, along with a technology path that includes rear contact and HJT for modules.

The company also referenced an INR 4,000 crore MoU with the Government of Gujarat as a step toward building an integrated manufacturing ecosystem.

BESS and exports: positioned, but not yet a near-term driver

On BESS, the company sounded measured. It said it is evaluating containerised BESS manufacturing with identified technology partners and that BESS will be housed in a separate subsidiary. It did not provide commercial timelines or financial targets on the call beyond the broader roadmap.

Exports were discussed in a similarly pragmatic manner. Management acknowledged aggressive pricing by Chinese competitors and stated that Solex targets geographies where there is a preference for Indian modules. It referenced Europe, the Middle East, and Africa as current focus markets and said the company is also trying to establish presence in the US. However, it also stated that export revenue is expected to be on the lower side in FY27.

Takeaways from the quarter

Solex’s Q1 FY27 performance underlines the operating leverage inherent in a scaled module business. Revenue held up, but profitability fell sharply as higher depreciation and finance costs met softer volumes. Management’s core argument is that this is seasonal and policy-driven, and that execution is expected to be H2-heavy.

The bigger investor lens is now shifting toward the cell project. The company is tying its next phase of margin expansion to backward integration, while attempting to de-risk execution through external operational expertise and structured financing. If the end-2027 commissioning target for the first 2.2 GW phase stays on track, the project could become the key milestone that changes how investors evaluate Solex beyond near-term quarterly volatility.